Karen Schreibers bevilling på 10 mio.
Karen Schreibers bevilling på 10 mio.
Det er med den største fornøjelse og dybeste respekt, at vi hylder vores læge Karen Schreiber. Hun har fra Novo Nordisk Fonden, fået bevilliget 10 mio. kr til at realisere det internationale lægemiddelstudie HYPATIA. Karen skal lede dette studie, der går på tværs af flere europæiske lande.
Studiet HYPATIA handler kort fortalt om at anvendelsen af medicinpræparatet hydroxychloroquine (Plaquenil) i sammenhæng med bindevævssygdommen Antiphospholipid syndrom (APS) og graviditet. Der er ikke gode overlevelseschancer for fostre, båret af kvinder med antifosfolipid antistoffer (aPL) og kvinder med aPL har en stor risiko for graviditetsforgiftning. HYPATIA studiet vil besvare spørgsmålet om hydroxychloroquine kan forbedre graviditetsudfald hos disse kvinder.
HYPATIA studiet forventes afsluttet i 2027.
Karen Schreiber receives DKK 10 million
Karen Schreiber receives DKK 10 million
Karen
Schreiber has received DKK 10 million for her research in order to improve Reproductive Health
Care in patients with rheumatic diseases.
It is with the greatest pleasure and
deepest respect that we pay tribute to our doctor Karen Schreiber. She has
received DKK 10 million from the Novo Nordisk Foundation. The amount will be
used to support the international study HYPATIA, which
spans several European countries.
The
study HYPATIA is a
randomized controlled study of hydroxychloroquine (Plaquenil) in pregnant patients
with antiphospholipid antibodies. These patients often suffer recurrent miscarriages,
intrauterine growth restriction, fetal death and pre-eclampsia. The HYPATIA study will
answer the question whether the addition of hydroxychloroquine to the current standard
of care can
improve pregnancy outcomes for these women.
